Mahana Therapeutics, Bayer Strike Commercialization Deal
Collaboration to focus on digital therapeutics.
Mahana Therapeutics has inked an agreement with the consumer health division of Bayer, aiming to commercialize digital therapeutics. The agreement, which comes amid Bayer’s recent launch of a new business unit focused on new digitally enabled precision health products, will focus on providing individuals with the opportunity control their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.
“This historic partnership is among the first major investments ever made by a global life sciences company into the emerging marketplace for digital therapeutics. Mahana is proud to collaborate with the Bayer team who share our view that digital therapeutics are a critical part of the future of healthcare,” said Simon Levy, CEO, Mahana, in a company press release. “Through this agreement, we can further expand the availability of our innovative prescription digital therapeutics for patients and their caregivers around the world who seek effective treatment for chronic conditions.”
Reference: Mahana Therapeutics Signs Agreement with Consumer Health Division of Bayer to Commercialize Digital Therapeutics. BusinessWire. August 22, 2023. Accessed August 24, 2023. https://www.businesswire.com/news/home/20230822680016/en/Mahana-Therapeutics-Signs-Agreement-with-Consumer-Health-Division-of-Bayer-to-Commercialize-Digital-Therapeutics
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
